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1. Introduction
  With the gradual development of the study on the genetic 
molecular biology techniques and human genomics, gene 
polymorphism is considered to be one of the important 
reasons for the differences of cancer between the 
individual. Cytochrome P450 1A1 (CYP1A1) as one of the 
most important phase栺metabolic detoxification enzymes in 
vivo has become the key enzyme involve in the metabolism 
of xenobiotic, its gene polymorphism has become the 
focus of the cancer research. In order to investigate the 
relationship between CYP1A1 genetic polymorphisms and 
the invasion and metastasis of breast cancer,the CYP1A1 
gene polymorphism was detected in 80 cases with breast 
cancer and 60 samples of normal breast tissue.
2. Materials and methods
2.1. General information
  Newly diagnosed patients with primary breast cancer 
were randomly selected from January 2012 to December 
2012 in our hospital. A total of 80 cases served as the 
observation group, aged from 29 to 75 years, the average 
age was (48.6暲16.3) years. All patients were in according 
to the diagnosis standard of breast cancer of the National 
Comprehensive Cancer Network guidelines, and did not 
receive chemotherapy. They had no family history of breast 
cancer or occupational exposure history of carcinogen. 
And 60 cases of healthy women who received normal 
physical examination in our hospital were selected as a 
normal control group at the same period, aged from 26 to 72 
years, the average age was (49.9暲14.7) years. The general 
information between the two groups showed no significant 
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difference (P> 0.05).
2.2. Main reagents and apparatus
  PCR primers were synthesized by Shanghai Sangon 
Bioengineering Technology Service Co., Ltd., Taq DNA 
polymerase and restriction endonuclease were purchased 
from MBI. Blood genomic DNA extraction kits were 
purchased from the Beijing TIANGEN Technology Co., 
Ltd., the automatic gel imaging analysis device and 
multifunctional PCR instrument were purchased from Bio-
Rad, USA. The multi-purpose electrophoresis tank was 
purchased from Shanghai KangHua Chemical and biological 
equipment company, high-speed freezing centrifuge was 
purchased from the MJ Research Inc company, USA.
2.3. Methods
  Two mL of fasting venous blood were obtained with 
EDTA anticoagulant vacuum tubes, mixed by gently 
inverting and placed in the -80 曟 refrigerator. DNA 
were extracted from all specimens according to the 
instructions of blood genomic DNA extraction kit, and then 
the  CYP1A1 genotype was analyzed by polymerase chain 
reaction restriction fragment length polymorphism (PCR-
RFLP) technique. The CYP1A1 primers were: upstream, 
5’-TAGGAGTCTTGTCTCATGCCT-3’, downstream, 5’-
AGCGGCTACACCTCTTCACTG 3’. PCR reaction conditions 
were: 94 曟 pre-denaturation for 5 min, then followed by 
cycles as follows: melted at 94 曟 for 35 s, annealed at 60 曟 
for 35 s, extended at 72 曟 for 60 s, after 33 cycles extended 
at 72 曟 for 7 min again. Amplified fragment was 340 bp, 
PCR amplification product was digested with the restriction 
endonuclease MspI at 37 曟 for 4 h. After 2% agarose gel 
electrophoresis,the photo are taken with PCR Gelation Image 
instrument and the digestion products were observed.
2.4. Determination
  Bio-Rad image analysis system was adopted to observe 
the banding pattern of electrophoresis results and then 
photographed. The CYP1A1 gene 3801 (T/C) polymorphism 
was in the performance of three genotypes: TT wild 
homozygous type (340 bp), the TC mutations in heterozygous 
genotype (340 bp, 200 bp, 140 bp), CC homozygous genotype 
(200 bp, 140 bp).
2.5. Statistical analysis
  All of the data were analyzed by SPSS16.0 statistics 
software. P<0.05 was considered as statistical significance. 
Hardy-Weinberg test was applied, P> 0.05 showed that the 
sampling may represent a genetic equilibrium population. 
氈
2 examination was used to test the genotype distribution 
frequency difference between the observation group and 
the control group, and the relationship between a variety of 
genotype and clinical features of breast cancer.
3. Results
3.1. CYP1A1 gene SNP-3801 (T / C) polymorphic loci RFLP 
typing results
  PCR-RFLP method was used to determine the CYP1A1 
gene SNP-3801 (T/C) polymorphism, if there was a T 濚 C 
mutation in the sequence of the gene polymorphism of its 
PCR product, there would be three types after the restriction 
enzyme: 
  TT wild homozygous type (340 bp), the TC mutations 
in heterozygous genotype (340 bp, 200 bp, 140 bp), CC 
homozygous genotype (200 bp, 140 bp) (Figure 1).
Figure 1. Three genotypes digested electrophoresis of two sites.
1: TT wild homozygous type (340 bp); 2: CC homozygous genotype (200 
bp, 140 bp); 3: TC mutations in heterozygous genotype (340 bp, 200 bp, 
140 bp).
  In the observation group, the expected values of wild-
type group, the heterozygous group and the homozygous 
mutations groups were 18, 50, 12, respectively. There 
was no statistically significant difference between them 
(氈
2=0.305, P=0.581). And in the control group, the expected 
values of wild-type group ,the heterozygous group and the 
homozygous mutations groups were 19, 27, 14, respectively. 
There was no statistically significant difference (氈
2=0.363, 
P=0.547), which showed the genotypes expected values 
and actual values were in good agreement between the 
observation group and control group. It indicated that it was 
accord with mendelian population genetics, and were able 
to represent the local female genetic equilibrium population 
(Table 1).
Table 1
Hardy-Weinberg equilibrium detection [n(%)].
Groups Practical frequency Theoretical frequency
TT TC CC TT TC CC
Observation group 
(n=80)
21(26.3) 46(57.5) 13(16.2) 18(22.5) 50(62.5) 12(15.0)
C o n t r o l  g r o u p 
(n=60)
16(26.7) 33(55.0) 11(18.3) 19(31.7) 27(45.0) 14(23.3)
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3.2. Frequency distribution of CYP1A1 gene 3801T濚C 
genotype and allele in patients with breast cancer and in 
normal group
  The frequency distribution of the TT wild homozygous type 
in the observation group and control group were 26.3% and 
26.7%, respectively, and the frequency distribution of the 
TC mutations in heterozygous genotype in the observation 
group and control group were 57.5% and 55.0%, respectively. 
Frequency distribution of the CC homozygous genotype in 
the observation group and control group were 16.2% and 
18.3%, respectively. There was no statistical significance 
difference in the genotype frequency distribution 
(氈
2=0.105, P=0. 746). The T allele frequency distribution of 
the observation group was 55.0%, in the control group was 
54.2%, without significant difference (氈
2=0.019, P=0.890) 
(Table 2).
Table 2 
Frequency distribution of CYP1A1 gene 3801T 濚C genotype and 
allele in the observation group and the control group [n(%)].
Groups Genotype Allele
TT TC CC T C
Observation group (n=80) 21(26.3) 46(57.5) 13(16.2) 88(55.0) 72(45.0)
Control group (n=60) 16(26.7) 33(55.0) 11(18.3) 65(54.2) 55(45.8)
3.3. Relationship between different CYP1A1 genotype breast 
cancers and prognostic factors
  With the increase of the clinical stage (P=0.006) and the 
number of lymph node metastasis (P=0.010), the proportion 
of the variability genotype (CYP1A1-CC) become larger. 
There was no significant correlation between the CYP1A1 
genotype and the age, tumor size and histological type of 
breast cancer patients (Table 3).
Table 3
Relationship of different CYP1A1 genotype breast cancers and 
prognostic factors.
Variable n TT TC CC P value 
Age (years) 曒50 18   6 10   2 0.502
<50 62 15 36 11
Size of the tumor 曒2 47   6 31 10 0.146
<2 33 15 15   3
Histological type Invasive ductal 70 16 42 12 0.567
Invasive lobular   3   2   1   0
Mucin cancer   2   1   1   0
Other factors   5   2   2   1
TNM staging 栺 11   3   6   2 0.006
栻A-栻B 54 15 34   5
栿 15   3   6   6
Lymph node metastasis Positive 25   5 12   8 0.010
Negative 55 16 34   5
4. Discussion
   Breast cancer is one of common female malignant tumors. 
In 2011, the United States released the latest statistics which 
showed that 230 480 cases American women are expected 
to develop breast cancer reach in 2011. Its high incidence 
ranks the top of female cancer incidence rate. In China, the 
researches showed the incidence rate is also increasing. But 
in recent years, with the improvement of molecular biology 
techniques and polyclinics, breast cancer mortality has been 
declining. Pathogenesis of breast cancer is not yet clear, but 
there were some progress in the research of the development 
of breast cancer invasion and metastasishas. At the present 
stage, prevention of the invasion and metastasis of breast 
cancer is a key in the treatment of breast cancer. Breast 
cancer cells will depart from the primary lesion and then 
attach to the metastatic sites. Local infiltration, invasion and 
metastasis of the breast cancer are complex process of the 
joint participation of multiple genes.
  It is considered that cytochrome P450 (cytochrome P450, 
CYP450) showed widely gene polymorphism, which can 
lead to obvious phenotypic polymorphism of individual 
differences and has a correlation with cancer susceptibility. 
Cytochrome P450 1A1 (cytochrome P450 1A1, CYP450 1A1) 
as endogenous compounds (hormones, fatty acids) and 
exogenous compounds (drugs, carcinogens, poisons) is 
an important member of the biotransformation enzymes 
and is closely related to the occurrence of tumor[1]. 
CYP4501A1 gene has 4 polymorphic sites, and CYP1A1*2A 
polymorphism is the 3’untranslated region, which is caused 
by mutations of 3801T濚C (poly (A) sites downstream about 
264 bp). There are three genotypes: TT-type (wild-type), TC 
(heterozygous-type) and CC (mutant-type), and all possess 
the Msp I identify restriction sites.
  The CYP1A1 gene polymorphism was detected by PCR and 
restriction fragment length polymorphism in 80 cases with 
breast cancer and 60 samples of normal breast tissue. The 
result showed if there is a T濚C mutation in the sequence 
of the gene polymorphism of its PCR product, there will be 
three types after the restriction enzyme: TT wild homozygous 
type (340 bp), TC mutations in heterozygous genotype (340 
bp, 200 bp, 140 bp), CC homozygous genotype (200 bp, 140 
bp). After Hardy-Weinberg equilibrium detection, our 
results showed that it is accord with mendelian population 
genetics, and were able to represent the local female genetic 
equilibrium population.
  In recent years, studies confirmed that the susceptibility 
of cervical cancer, lung cancer, endometrial cancer, 
chronic myeloid leukemia  and other malignancies 
may related with the gene polymorphism of cytochrome 
P4501A1. But some studies suggest that cytochrome 
P4501A1 gene polymorphism has nothing to do with the 
cancer incidence[2,3]. Zhang considered the mutant allele 
of the P4501A1 gene栺 leVal polymorphic can significantly 
increase the risk of endometrial cancer[4]. Shi et al reports 
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that the gene polymorphism of CYP1A1 mSAP栺 were 
related to the susceptibility of lung cancer, which may be 
associated with the gene mutation[5,6]. Zhu et al found that 
the occurrence of endometrial adenocarcinoma was related 
to the CYP1A1 gene exon 7 sub-Ile/Val genotype, which can 
be used as one of the indicators to screening endometrial 
adenocarcinoma susceptible population[7-9]. Jiang consider 
that the susceptibility of CML disease may be related to 
carrying CYP1A1C and the missing gene of GSTM1, T1[10,11].
  The study on correlation of CYP1A1*2A polymorphic loci 
and the breast cancer showed that the distribution frequency 
of the TT genotype, TC genotype and CC type in the 
observation group were 26.3%, 57.5% and 16.2%, respectively, 
and in the control group were 26.7%, 55.0% and 18.3%, 
respectively. There was no statistical significance difference 
in genotype frequency distribution. T allele frequency 
distribution of the observation group and the control group 
were 55.0% and 54.2%, respectively; and C allele frequency 
distribution of the observation group and the control group 
were 45.0% and 45.8%, respectively, without significant 
difference.
  The above results suggest that the gene frequency 
distribution of CYP1A1*2A polymorphism had no 
statistically significant difference in breast cancer, which 
is consistent with the report of Guo[12-15]. The results of the 
prognostic factors in patients with breast cancer and three 
genotypes of the CYP1A1*2A showed that the proportion 
of CC homozygous genotype will increase with the clinical 
stage of breast cancer, which was positively correlated to 
the increase of the number of lymph node metastasis in the 
process of cancer invasion and metastasis. There was no 
relevance between three genotypes and the age, the tumor 
size and histological type of the patients with breast cancer. 
These suggested that in the process of the invasion and 
metastasis of breast cancer, patients with CYP1A1*2A gene 
CC sites have a worse prognosis, so the clinical detection of 
CYP1A1*2A gene CC allele has prognostic value.
  In summary, there is a correlation between the CYP1A1 CC 
allele and some factors, including lymph node metastases as 
well as clinical stage, which can significantly increase the 
risk of breast cancer.
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